EVO
Evotec SE
Price Chart
Latest Quote
$1.80
-0.08 (-4.26%)
Current Price
| Previous Close | $1.88 |
| Open | $1.85 |
| Day High | $1.85 |
| Day Low | $1.80 |
| Volume | 38,241 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 355.39M |
| Total Debt | $551.60M |
| Cash Equivalents | $539.69M |
| Revenue | $831.44M |
| Net Income | $-228.41M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $639.70M |
| EPS (TTM) | $-0.64 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $678.33M |
| Sales | $831.44M |
| Income | $-228.41M |
| Book/sh | $2.18 |
| Cash/sh | $1.31 |
| Employees | 4K |
Financial Ratios
| Quick Ratio | 2.02 |
| Current Ratio | 2.33 |
| Debt/Eq | 71.50 |
Returns & Margins
| ROA | -5.39% |
| ROE | -26.07% |
| Gross Margin | 8.46% |
| Operating Margin | -62.26% |
| Profit Margin | -27.47% |
Ownership
| Insider Ownership | 0.01% |
| Institutional Ownership | 0.81% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.47 |
| PEG | 1.42 |
| P/S | 0.89 |
| P/B | 0.82 |
Analyst Data
| Recommendation | none |
| Target Price | $3.83 |
Technical Indicators
| SMA20 | $1.97 |
| SMA50 | $2.20 |
| SMA200 | $2.86 |
| RSI | 30.77 |
| ATR | 0.0736 |
| Shares Float | 270.77M |
| Short Float | 0.01% |
| Short Ratio | 0.64 |
| Volatility | 1.26 |
| Rel Volume | 0.62 |
Performance History
| Week | -4.76% |
| Month | -5.76% |
| Quarter | -41.37% |
| 6 Months | -45.12% |
| YTD | -43.40% |
| Year | -48.72% |
| 3 Years | -84.08% |
| 5 Years | -93.12% |
| 10 Years | -28.43% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $1.80 | 38,241 |
| 2026-08-31 | $1.88 | 65,800 |
| 2026-08-28 | $1.91 | 28,200 |
| 2026-08-27 | $1.97 | 31,300 |
| 2026-08-26 | $1.95 | 31,100 |
| 2026-08-25 | $1.89 | 25,300 |
| 2026-08-24 | $1.89 | 22,600 |
| 2026-08-21 | $1.93 | 40,900 |
| 2026-08-20 | $1.96 | 79,200 |
| 2026-08-19 | $1.98 | 34,900 |
| 2026-08-18 | $1.91 | 21,900 |
| 2026-08-17 | $1.96 | 30,200 |
| 2026-08-14 | $1.96 | 42,000 |
| 2026-08-13 | $2.02 | 28,500 |
| 2026-08-12 | $2.19 | 49,400 |
| 2026-08-11 | $2.10 | 50,500 |
| 2026-08-10 | $2.08 | 49,800 |
| 2026-08-07 | $2.00 | 49,400 |
| 2026-08-06 | $1.95 | 66,800 |
| 2026-08-05 | $1.98 | 455,000 |
| 2026-08-04 | $1.95 | 16,200 |
| 2026-08-03 | $1.94 | 79,000 |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just  Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
đ° Latest News
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
Simply Wall St. âĸ 2026-08-11T00:19:32Z
Evotec and Odyssey collaborate on AI-enabled R&D
Pharmaceutical Technology âĸ 2026-08-07T10:10:37Z
Health Care Roundup: Market Talk
The Wall Street Journal âĸ 2026-07-16T21:05:00Z
Evotec SE (EVO) Q2 2026 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
GuruFocus.com âĸ 2026-07-14T19:00:29ZEvotec Q2 Earnings Call Highlights
MarketBeat âĸ 2026-07-14T13:03:08Z
Assessing Evotec (XTRA:EVT) Valuation After Recent Share Weakness And Ongoing Losses
Simply Wall St. âĸ 2026-06-09T01:10:10Z
QuickLogic Posts Downbeat Q1 Results, Joins Resideo Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga âĸ 2026-05-13T12:02:07Z
Evotec (EVO) Nominates First Preclinical Development Candidate from Almirall Alliance
Insider Monkey âĸ 2026-05-13T06:23:50Z
European Market: Nokian Renkaat Oyj And Two Other Stocks That May Be Priced Below Estimated Value
Simply Wall St. âĸ 2026-05-11T10:37:55Z
European Stocks Estimated To Be Up To 30.8% Below Their Intrinsic Value
Simply Wall St. âĸ 2026-05-11T05:37:48Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Cost Of Revenue | $787,192,864 | $796,457,226 | $708,051,111 | $674,197,773 |
| Total Revenue | $920,566,281 | $930,601,311 | $912,454,418 | $877,449,749 |
| Operating Revenue | $920,566,281 | $930,601,311 | $912,454,418 | $877,449,749 |
| Expenses | ||||
| Interest Expense | $16,863,614 | $13,660,672 | $13,707,379 | $15,354,974 |
| Total Expenses | $985,743,765 | $1,022,753,338 | $943,547,363 | $853,103,650 |
| Other Income Expense | $-24,439,513 | $-123,532,222 | $-60,122,603 | $-198,496,021 |
| Other Non Operating Income Expenses | $-21,916,160 | $742,644 | $-833,723 | $14,429,004 |
| Net Non Operating Interest Income Expense | $-11,697,804 | $-10,817,375 | $-2,891,172 | $-5,621,205 |
| Interest Expense Non Operating | $16,863,614 | $13,660,672 | $13,707,379 | $15,354,974 |
| Operating Expense | $198,550,901 | $226,296,113 | $235,496,252 | $178,905,877 |
| Other Operating Expenses | $-2,133,349 | $-11,598,552 | $-744,979 | $-55,230,030 |
| Selling And Marketing Expense | $20,289,583 | $20,408,687 | $19,697,570 | $15,753,152 |
| General And Administrative Expense | $185,187,988 | $199,349,594 | $178,352,397 | $166,626,569 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-120,874,586 | $-228,956,085 | $-97,983,414 | $-205,108,584 |
| Net Interest Income | $-11,697,804 | $-10,817,375 | $-2,891,172 | $-5,621,205 |
| Interest Income | $5,165,810 | $2,843,297 | $10,816,207 | $9,733,769 |
| Normalized Income | $-119,806,627 | $-127,602,224 | $-68,184,782 | $-39,107,483 |
| Net Income From Continuing And Discontinued Operation | $-120,874,586 | $-228,956,085 | $-97,983,414 | $-205,108,584 |
| Total Operating Income As Reported | $-65,643,388 | $-166,419,889 | $-55,472,907 | $24,346,099 |
| Net Income Common Stockholders | $-120,874,586 | $-228,956,085 | $-97,983,414 | $-205,108,584 |
| Net Income | $-120,874,586 | $-228,956,085 | $-97,983,414 | $-205,108,584 |
| Net Income Including Noncontrolling Interests | $-120,874,586 | $-228,956,085 | $-97,983,414 | $-205,108,584 |
| Net Income Continuous Operations | $-120,874,586 | $-228,957,252 | $-97,983,414 | $-205,108,584 |
| Pretax Income | $-101,314,801 | $-226,502,792 | $-94,106,721 | $-179,772,294 |
| Special Income Charges | $-465,904 | $-74,269,030 | $-24,381,129 | $5,730,967 |
| Earnings From Equity Interest | $-1,266,931 | $-5,035,030 | $-24,231,666 | $-17,629,612 |
| Interest Income Non Operating | $5,165,810 | $2,843,297 | $10,816,207 | $9,733,769 |
| Operating Income | $-65,177,484 | $-92,152,027 | $-31,092,946 | $24,346,099 |
| Gross Profit | $133,373,417 | $134,144,085 | $204,403,307 | $203,251,976 |
| Per Share | ||||
| Diluted EPS | $-0.34 | $-0.65 | $-0.27 | $-0.58 |
| Basic EPS | $-0.34 | $-0.65 | $-0.27 | $-0.58 |
| Other | ||||
| Tax Effect Of Unusual Items | $-188,463 | $-17,885,975 | $-5,258,582 | $-29,294,312 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $32,961,232 | $25,054,880 | $63,227,461 | $128,024,282 |
| Total Unusual Items | $-1,256,422 | $-119,239,836 | $-35,057,215 | $-195,295,414 |
| Total Unusual Items Excluding Goodwill | $-1,256,422 | $-119,239,836 | $-35,057,215 | $-195,295,414 |
| Reconciled Depreciation | $116,155,996 | $118,657,164 | $108,569,589 | $97,146,189 |
| EBITDA (Bullshit earnings) | $31,704,809 | $-94,184,956 | $28,170,246 | $-67,271,132 |
| EBIT | $-84,451,187 | $-212,842,120 | $-80,399,342 | $-164,417,321 |
| Diluted Average Shares | $414,708,673 | $414,047,701 | $413,163,603 | $412,597,694 |
| Basic Average Shares | $414,708,673 | $414,047,701 | $413,163,603 | $412,597,694 |
| Diluted NI Availto Com Stockholders | $-120,874,586 | $-228,956,085 | $-97,983,414 | $-205,108,584 |
| Tax Provision | $19,559,784 | $2,454,460 | $3,876,693 | $25,336,290 |
| Gain On Sale Of Business | $2,234,937 | - | - | - |
| Other Special Charges | $1,961,700 | $10,128,444 | $18,529,892 | - |
| Impairment Of Capital Assets | $0 | $0 | $5,851,237 | $0 |
| Restructuring And Mergern Acquisition | $739,141 | $64,140,585 | $0 | $-5,730,967 |
| Gain On Sale Of Security | $-790,518 | $-44,970,806 | $-10,676,085 | $-201,026,380 |
| Other Taxes | $-48,591,777 | $-41,248,247 | $-41,828,583 | $-37,737,037 |
| Research And Development | $43,798,457 | $59,384,631 | $80,019,847 | $89,493,223 |
| Selling General And Administration | $205,477,571 | $219,758,280 | $198,049,967 | $182,379,721 |
| Other Gand A | $185,187,988 | $199,349,594 | $178,352,397 | $166,626,569 |
| Minority Interests | - | - | - | $0 |
| Write Off | - | - | - | $-1,011,210 |
Fetched: 2026-08-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $595,245,185 | $751,085,906 | $967,794,210 | $1,037,536,149 |
| Total Assets | $2,001,336,898 | $2,233,187,658 | $2,630,158,681 | $2,635,739,017 |
| Total Non Current Assets | $1,110,462,349 | $1,436,872,889 | $1,575,555,741 | $1,382,036,367 |
| Other Non Current Assets | $593,181 | $4,046,006 | $978,515 | $4,419,664 |
| Non Current Deferred Assets | $3,443,484 | $20,239,373 | $16,732,834 | $12,058,617 |
| Non Current Deferred Taxes Assets | $3,443,484 | $20,239,373 | $16,732,834 | $12,058,617 |
| Non Current Accounts Receivable | $42,443,949 | $40,117,934 | $110,220,686 | $82,079,632 |
| Investmentin Financial Assets | $56,053,244 | $46,723,492 | $4,005,138 | $3,791,452 |
| Goodwill And Other Intangible Assets | $354,899,563 | $361,157,153 | $339,898,396 | $348,713,202 |
| Other Intangible Assets | $36,864,781 | $30,874,590 | $18,045,305 | $27,812,937 |
| Current Assets | $890,874,549 | $796,314,769 | $1,054,602,940 | $1,253,702,650 |
| Other Current Assets | $827,884 | $10,662,073 | $17,641,288 | $24,690,564 |
| Assets Held For Sale Current | $4,472,209 | - | - | - |
| Restricted Cash | $39,224,660 | $39,016,813 | $13,800,793 | $16,882,297 |
| Prepaid Assets | $22,150,863 | $25,969,172 | $21,479,448 | $19,789,817 |
| Inventory | $34,232,834 | $36,340,493 | $36,069,592 | $34,826,014 |
| Receivables | $249,313,393 | $254,998,820 | $259,106,714 | $322,011,895 |
| Other Receivables | $33,039,466 | $53,752,917 | $29,191,965 | $35,632,880 |
| Taxes Receivable | $57,512,842 | $65,422,697 | $115,019,845 | $85,774,167 |
| Accounts Receivable | $158,761,085 | $135,823,207 | $114,894,904 | $200,604,848 |
| Allowance For Doubtful Accounts Receivable | $-16,447,921 | $-13,009,107 | $-7,535,030 | $-3,763,428 |
| Gross Accounts Receivable | $175,209,006 | $148,832,314 | $122,429,934 | $204,368,276 |
| Cash Cash Equivalents And Short Term Investments | $540,652,707 | $429,327,397 | $705,407,487 | $825,909,583 |
| Cash And Cash Equivalents | $469,156,914 | $342,662,291 | $596,576,338 | $467,884,144 |
| Cash Equivalents | $273,302,182 | $4,159,271 | $319,180,275 | $214,315,730 |
| Cash Financial | $195,854,732 | $338,503,020 | $277,396,064 | $253,568,414 |
| Hedging Assets Current | - | $5,009,341 | $14,898,411 | $9,592,480 |
| Debt | ||||
| Net Debt | $27,698,504 | $175,247,540 | $134,633,343 | - |
| Total Debt | $522,756,865 | $517,909,831 | $731,209,681 | $591,632,387 |
| Long Term Debt And Capital Lease Obligation | $401,690,780 | $458,597,596 | $557,113,472 | $572,504,644 |
| Long Term Debt | $401,690,780 | $458,597,596 | $557,113,472 | $383,343,046 |
| Current Debt And Capital Lease Obligation | $121,066,085 | $59,312,234 | $174,096,209 | $19,127,743 |
| Current Debt | $95,164,638 | $59,312,234 | $174,096,209 | $1,816,908 |
| Other Current Borrowings | $95,164,638 | - | $151,764,355 | $1,816,908 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,051,192,151 | $1,120,944,599 | $1,322,466,075 | $1,249,489,666 |
| Total Non Current Liabilities Net Minority Interest | $621,400,018 | $718,580,069 | $779,994,125 | $855,157,596 |
| Other Non Current Liabilities | $2,002,569 | $1,531,994 | $1,620,738 | $1,140,822 |
| Non Current Deferred Liabilities | $196,647,585 | $235,581,493 | $202,503,494 | $262,330,674 |
| Non Current Deferred Taxes Liabilities | $17,205,744 | $16,950,023 | $21,178,187 | $21,630,078 |
| Current Liabilities | $429,792,133 | $402,364,530 | $542,471,950 | $394,332,069 |
| Other Current Liabilities | $12,964,735 | $16,332,321 | $17,925,034 | $20,618,869 |
| Current Deferred Liabilities | $126,189,859 | $128,228,625 | $125,939,975 | $159,586,634 |
| Payables And Accrued Expenses | $94,620,500 | $116,494,623 | $166,600,880 | $126,243,572 |
| Payables | $94,620,500 | $116,494,623 | $166,600,880 | $126,243,572 |
| Total Tax Payable | $18,998,131 | $16,317,141 | $9,759,458 | $12,655,301 |
| Income Tax Payable | $12,351,704 | $9,945,119 | $6,498,131 | $10,493,928 |
| Accounts Payable | $75,622,369 | $100,177,482 | $156,841,422 | $113,588,271 |
| Equity | ||||
| Common Stock Equity | $950,144,748 | $1,112,243,058 | $1,307,692,606 | $1,386,249,351 |
| Total Equity Gross Minority Interest | $950,144,748 | $1,112,243,058 | $1,307,692,606 | $1,386,249,351 |
| Stockholders Equity | $950,144,748 | $1,112,243,058 | $1,307,692,606 | $1,386,249,351 |
| Gains Losses Not Affecting Retained Earnings | $-52,669,311 | $-8,578,935 | $-35,781,175 | $-43,673,515 |
| Other Equity Adjustments | $-52,669,311 | $-8,578,935 | $-35,781,175 | $-43,673,515 |
| Retained Earnings | $-905,986,646 | $-785,112,060 | $-556,153,640 | $-458,170,226 |
| Long Term Equity Investment | $5,405,184 | $2,496,497 | $3,585,941 | $18,733,068 |
| Other Equity Interest | - | $1,168 | $1,168 | - |
| Other | ||||
| Treasury Shares Number | $373,081 | $195,487 | $291,820 | $291,820 |
| Ordinary Shares Number | $207,215,544 | $207,325,371 | $206,895,992 | $206,623,826 |
| Share Issued | $207,588,625 | $207,520,858 | $207,187,813 | $206,915,647 |
| Tangible Book Value | $595,245,185 | $751,085,906 | $967,794,210 | $1,037,536,149 |
| Invested Capital | $1,447,000,166 | $1,630,152,889 | $2,038,902,286 | $1,771,409,305 |
| Working Capital | $461,082,416 | $393,950,238 | $512,130,989 | $859,370,581 |
| Capital Lease Obligations | $25,901,447 | - | $220,854,730 | $206,472,433 |
| Total Capitalization | $1,351,835,527 | $1,570,840,655 | $1,864,806,078 | $1,769,592,397 |
| Treasury Stock | $1,807,566 | $0 | - | - |
| Additional Paid In Capital | $1,703,019,537 | $1,698,608,047 | $1,692,729,953 | $1,681,468,861 |
| Capital Stock | $207,588,734 | $207,324,838 | $206,896,300 | $206,624,231 |
| Common Stock | $207,588,734 | $207,324,838 | $206,896,300 | $206,624,231 |
| Non Current Deferred Revenue | $179,441,841 | $218,631,470 | $181,325,307 | $240,700,596 |
| Long Term Provisions | $21,059,084 | $22,868,985 | $18,756,421 | $19,181,456 |
| Current Deferred Revenue | $126,189,859 | $128,228,625 | $125,939,975 | $159,586,634 |
| Current Capital Lease Obligation | $25,901,447 | - | $22,320,176 | $17,310,835 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,591,546 | $9,344,932 | $5,171,649 | $5,221,859 |
| Current Provisions | $68,359,408 | $72,651,795 | $52,738,204 | $63,533,393 |
| Investments And Advances | $61,458,428 | $49,219,988 | $165,920,123 | $175,539,459 |
| Available For Sale Securities | $56,053,244 | $46,723,492 | $4,005,138 | $3,791,452 |
| Goodwill | $318,034,782 | $330,282,563 | $321,853,091 | $320,900,265 |
| Net PPE | $647,623,744 | $962,092,435 | $941,805,187 | $759,225,793 |
| Accumulated Depreciation | $-606,660,411 | $-557,746,354 | $-409,050,658 | $-315,984,338 |
| Gross PPE | $1,254,284,154 | $1,519,838,789 | $1,350,855,845 | $1,075,210,132 |
| Leases | $276,210,870 | $259,953,281 | $291,748,001 | $260,081,725 |
| Construction In Progress | $29,927,603 | $294,551,598 | $263,480,838 | $135,895,603 |
| Other Properties | $17,881,830 | $5,025,689 | $4,963,802 | $5,474,077 |
| Machinery Furniture Equipment | $563,751,725 | $583,070,967 | $470,328,096 | $393,132,863 |
| Buildings And Improvements | $366,512,127 | $377,237,255 | $320,335,109 | $280,625,863 |
| Properties | $0 | $0 | $0 | $0 |
| Work In Process | $2,724,194 | $1,946,520 | $5,825,549 | $2,227,931 |
| Raw Materials | $31,508,639 | $34,393,973 | $30,244,043 | $32,598,083 |
| Other Short Term Investments | $71,495,793 | $86,665,106 | $108,831,149 | $358,025,439 |
| Other Investments | - | $46,723,492 | $162,334,182 | $153,014,939 |
| Long Term Capital Lease Obligation | - | - | $198,534,554 | $189,161,598 |
| Minority Interest | - | - | - | $0 |
| Line Of Credit | - | - | - | $1,816,908 |
| Duefrom Related Parties Current | - | - | - | $3,673,517 |
Fetched: 2026-08-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-107,194,063 | $-133,135,211 | $-209,667,202 | $28,557,916 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,718,122 | $21,275,104 | $42,549,041 | $240,321,100 |
| Cash Flow From Continuing Operating Activities | $-10,721,625 | $21,275,104 | $42,546,705 | $240,321,100 |
| Operating Gains Losses | $-8,512,377 | $15,133,115 | $24,231,666 | $17,629,612 |
| Investing Activities | ||||
| Capital Expenditure | $-96,475,941 | $-154,410,315 | $-252,216,242 | $-211,763,185 |
| Investing Cash Flow | $200,363,139 | $-83,123,536 | $-15,519,616 | $-482,014,223 |
| Cash Flow From Continuing Investing Activities | $200,361,971 | $-83,122,369 | $-15,519,616 | $-482,014,223 |
| Net Other Investing Changes | $1,168 | $5,067,725 | - | $-4,819,010 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,807,566 | $0 | $0 | - |
| Financing Cash Flow | $-43,939,746 | $-188,487,847 | $84,029,655 | $-67,894,672 |
| Cash Flow From Continuing Financing Activities | $-43,939,746 | $-188,486,680 | $84,029,655 | $-67,894,672 |
| Net Other Financing Charges | $-1,709,481 | $-4,432,508 | - | - |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $-1,807,566 | $0 | $0 | $414,526 |
| Dividends Received Cfi | $1,229,566 | $0 | $0 | - |
| Issuance Of Capital Stock | - | $0 | $255,722 | $414,526 |
| Common Stock Issuance | - | $0 | $255,722 | $414,526 |
| Other | ||||
| Repayment Of Debt | $-85,683,088 | $-178,623,298 | $-158,017,274 | $-62,018,913 |
| Issuance Of Debt | $51,332,319 | $1,050,911 | $256,799,381 | $0 |
| End Cash Position | $488,693,345 | $357,761,543 | $596,577,506 | $484,767,609 |
| Beginning Cash Position | $357,761,543 | $596,577,506 | $484,767,609 | $816,588,005 |
| Effect Of Exchange Rate Changes | $-14,773,470 | $11,520,317 | $751,985 | $-22,232,601 |
| Changes In Cash | $145,705,271 | $-250,336,280 | $111,057,912 | $-309,587,795 |
| Interest Paid Cff | $-6,334,656 | $-6,912,657 | $-15,008,173 | $-6,691,966 |
| Proceeds From Stock Option Exercised | $262,728 | $429,706 | $255,722 | $401,681 |
| Common Stock Payments | $-1,807,566 | $0 | $0 | - |
| Net Issuance Payments Of Debt | $-34,350,769 | $-177,572,388 | $98,782,107 | $-62,018,913 |
| Net Long Term Debt Issuance | $-34,350,769 | $-177,572,388 | $98,782,107 | $-62,018,913 |
| Long Term Debt Payments | $-85,683,088 | $-178,623,298 | $-158,017,274 | $-62,018,913 |
| Long Term Debt Issuance | $51,332,319 | $1,050,911 | $256,799,381 | $0 |
| Interest Received Cfi | $4,803,830 | $6,593,881 | $12,102,989 | $3,533,395 |
| Net Investment Purchase And Sale | $37,328,349 | $7,331,854 | $247,515,168 | $-175,911,949 |
| Sale Of Investment | $37,328,349 | $41,647,593 | $304,020,303 | $239,567,948 |
| Purchase Of Investment | $0 | $-34,315,739 | $-56,505,135 | $-415,479,896 |
| Net Business Purchase And Sale | $253,226,284 | $49,957,961 | $-23,540,401 | $-97,872,485 |
| Sale Of Business | $269,537,587 | $81,001,864 | $4,068,192 | $0 |
| Purchase Of Business | $-16,311,302 | $-31,043,903 | $-27,608,593 | $-97,872,485 |
| Net Intangibles Purchase And Sale | $-11,770,200 | $-17,245,445 | $-3,125,876 | $0 |
| Purchase Of Intangibles | $-11,770,200 | $-17,245,445 | $-3,125,876 | $0 |
| Net PPE Purchase And Sale | $-84,455,858 | $-134,829,513 | $-248,471,497 | $-211,763,185 |
| Sale Of PPE | $249,883 | $2,335,357 | $618,870 | $0 |
| Purchase Of PPE | $-84,705,741 | $-137,164,870 | $-249,090,367 | $-211,763,185 |
| Taxes Refund Paid | $17,259,457 | $88,840,491 | $-15,065,389 | $-21,602,054 |
| Change In Working Capital | $-70,999,530 | $-79,643,854 | $-11,611,396 | $122,939,041 |
| Change In Other Working Capital | $-17,759,224 | $29,159,270 | $-117,496,491 | $228,215,776 |
| Change In Payables And Accrued Expense | $-8,528,724 | $-58,092,010 | $22,213,918 | $62,985,751 |
| Change In Payable | $-8,528,724 | $-58,092,010 | $22,213,918 | $62,985,751 |
| Change In Account Payable | $-8,528,724 | $-58,092,010 | $22,213,918 | $28,665,342 |
| Change In Inventory | $-11,165,343 | $-3,137,552 | $-1,872,956 | $-5,149,463 |
| Change In Receivables | $-33,546,238 | $-47,573,562 | $85,544,134 | $-62,680,987 |
| Changes In Account Receivables | $-33,546,238 | $-47,573,562 | $85,544,134 | $-44,872,721 |
| Other Non Cash Items | $33,851,003 | $38,493,693 | $2,759,225 | $-8,627,977 |
| Stock Based Compensation | $4,411,490 | $5,879,262 | $11,244,745 | $11,582,204 |
| Unrealized Gain Loss On Investment Securities | $-2,500,000 | $46,177,018 | $10,676,085 | $201,026,380 |
| Asset Impairment Charge | $930,640 | $14,239,841 | $5,851,237 | $0 |
| Deferred Tax | $19,559,784 | $2,454,460 | $3,876,693 | $25,336,290 |
| Deferred Income Tax | $19,559,784 | $2,454,460 | $3,876,693 | $25,336,290 |
| Depreciation Amortization Depletion | $116,155,996 | $118,657,164 | $108,569,589 | $97,146,189 |
| Depreciation And Amortization | $116,155,996 | $118,657,164 | $108,569,589 | $97,146,189 |
| Earnings Losses From Equity Investments | $1,266,931 | $5,035,030 | $24,231,666 | $17,629,612 |
| Gain Loss On Investment Securities | $-14,158,103 | - | - | - |
| Gain Loss On Sale Of Business | $4,378,795 | $10,098,085 | $0 | $0 |
| Net Income From Continuing Operations | $-120,874,586 | $-228,956,085 | $-97,983,414 | $-205,108,584 |
| Depreciation | - | - | $108,569,589 | $84,863,378 |
| Interest Received Cfo | - | - | - | $3,533,395 |
| Interest Paid Cfo | - | - | - | $-11,440,915 |
| Change In Other Current Liabilities | - | - | - | $10,852,405 |
| Change In Other Current Assets | - | - | - | $-94,964,965 |
| Change In Tax Payable | - | - | - | $34,320,409 |
| Change In Income Tax Payable | - | - | - | $34,320,409 |
| Amortization Cash Flow | - | - | - | $10,488,089 |
| Amortization Of Intangibles | - | - | - | $10,488,089 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $-11,003,035 |
| Gain Loss On Sale Of PPE | - | - | - | $207,847 |
Fetched: 2026-08-20